Vanguard Group Inc Galectin Therapeutics Inc Call Options Transaction History
Vanguard Group Inc
- $4.96 Trillion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding GALT
# of Institutions
65Shares Held
7.62MCall Options Held
61.2KPut Options Held
0-
Advisor Group Holdings, Inc. Phoenix, AZ1.26MShares$2.88 Million0.01% of portfolio
-
Black Rock Inc. New York, NY713KShares$1.62 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA567KShares$1.29 Million0.0% of portfolio
-
Geneos Wealth Management Inc.409KShares$932,1770.05% of portfolio
-
Wealthspire Advisors, LLC New York, NY398KShares$908,2920.01% of portfolio
About GALECTIN THERAPEUTICS INC
- Ticker GALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,426,000
- Market Cap $135M
- Description
- Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...